Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03993210 · ClinicalTrials.gov registry record · NA
The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids
A NA study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03993210 is a NA study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 1 participants.
The verdict
NCT03993210, a NA study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research study is to evaluate if these new MRI methods can give additional information in characterizing gynecological tumors compared with conventional MRI.
Interventions
- DEVICE Magnetic Resonance Fingerprinting (MRF)
- DEVICE Q-space Trajectory Imaging (QTI)
- DEVICE Magnetic Resonance Imaging Machine (MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-09-18 |
| Est. Completion | 2019-09-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03993210
The ClinicalTrials.gov registry entry for NCT03993210 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Fingerprinting (MRF) is the first listed.
NCT03993210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03993210 about?
NCT03993210 is a clinical study titled "The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids". This research is being done to test new MRI methods called Magnetic Resonance Fingerprinting and Q-space Trajectory Imaging in gynecological abnormalities. The purpose of this research study is to evaluate if these new MRI methods can give additional information in characterizing gynecological tumor...
What is the current status of trial NCT03993210?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2019-09-18. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT03993210?
The interventions under investigation include: Magnetic Resonance Fingerprinting (MRF) (DEVICE), Q-space Trajectory Imaging (QTI) (DEVICE), Magnetic Resonance Imaging Machine (MRI) (DEVICE).
Who is sponsoring clinical trial NCT03993210?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.